Targeting the Bcl-2 Family in Cancer Therapy

Seminars in Oncology

Volumn 33, Issue 4, 2006, Pages 449-456

  Papadopoulos, Kyriakos ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOGOSSYPOL; BH 3L; BH3 PROTEIN; BID HYDROCARBON STAPLED STABILIZED ALPHA HELIX PROTEIN OF BCL 2 DOMAIN; BIM PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIGALLOCATECHIN; FLUDARABINE; GOSSYPOL; GX 15 070; MICRORNA; MICRORNA 15; MICRORNA 16; OBLIMERSEN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; SPC 2996; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADRENAL CORTEX TUMOR; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATAXIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME DELETION 13; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DROWSINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TARGETING; DYSAUGUSIA; FATIGUE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; LIVER TOXICITY; LYMPHOMA; MELANOMA; MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER;

EID: 33746700186     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.04.008     Document Type: Article

References (99)

1. Danial N.N., and Korsmeyer S.J. Cell death. Critical control points. Cell 116 (2004) 205-219
2. Bakhshi A., Jensen J.P., Goldman P., et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas. Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41 (1985) 899-906
3. Cleary M.L., and Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 82 (1985) 7439-7443
4. Tsujimoto Y., Cossman J., Jaffe E., et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228 (1985) 1440-1443
5. Letai A., Bassik M.C., Walensky L.D., et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
6. Kuwana T., Bouchier-Hayes L., Chipuk J.E., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17 (2005) 525-535
7. Wei M.C., Zong W.X., Cheng E.H., et al. Proapoptotic BAX and BAK. a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
8. Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 115 (2005) 2648-2655
9. Puthalakath H., and Strasser A. Keeping killers on a tight leash. Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9 (2002) 505-512
10. Li H., Zhu H., Xu C.J., et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
11. Oda E., Ohki R., Murasawa H., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
12. Yu J., Zhang L., Hwang P.M., Kinzler K.W., et al. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7 (2001) 673-682
13. Luciano F., Jacquel A., Colosetti P., et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22 (2003) 6785-6793
14. Cheng E.H., Wei M.C., Weiler S., et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8 (2001) 705-711
15. Chen L., Willis S.N., Wei A., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 (2005) 393-403
16. Cuddeback S.M., Yamaguchi H., Komatsu K., et al. Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. J Biol Chem 276 (2001) 20559-20565
17. Guo B., Zhai D., Cabezas E., et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423 (2003) 456-461
18. Sawada M., Sun W., Hayes P., et al. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 5 (2003) 320-329
19. Sharpe J.C., Arnoult D., and Youle R.J. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 1644 (2004) 107-113
20. + cells. Br J Haematol 118 (2002) 521-534
21. Bairey O., Zimra Y., Shaklai M., et al. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 5 (1999) 2860-2866
22. Sohn S.K., Jung J.T., Kim D.H., et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol 73 (2003) 101-107
23. Garcia E.J., Lawson D., Cotsonis G., et al. Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x). Prognostic significance. Appl Immunohistochem Mol Morphol 10 (2002) 210-217
24. Watanabe J., Kushihata F., Honda K., et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135 (2004) 604-612
25. Wuilleme-Toumi S., Robillard N., Gomez P., et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19 (2005) 1248-1252
26. Kitada S., Andersen J., Akar S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia. Correlations with in vitro and in vivo chemoresponses. Blood 91 (1998) 3379-3389
27. Saxena A., Viswanathan S., Moshynska O., et al. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 75 (2004) 22-33
28. Crooke S.T. Molecular mechanisms of antisense drugs. RNase H. Antisense Nucleic Acid Drug Dev 8 (1998) 133-134
29. Dias N., and Stein C.A. Antisense oligonucleotides. basic concepts and mechanisms. Mol Cancer Ther 1 (2002) 347-355
30. Simoes-Wust A.P., Hopkins-Donaldson S., Sigrist B., et al. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 14 (2004) 199-209
31. Hansen B., Westergaard M., Frieden M., et al. SPC2996-A Bcl-2 inhibitor for treatment of chronic lymphocytic leukemia. Clin Cancer Res 11 suppl (2005) 66 abstr A41
32. Reed J.C., Stein C., Subasinghe C., et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival. Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50 (1990) 6565-6570
33. Jansen B., Schlagbauer-Wadl H., Brown B.D., et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 (1998) 232-234
34. Klasa R.J., Bally M.B., Ng R., et al. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6 (2000) 2492-2500
35. Schlagbauer-Wadl H., Klosner G., Heere-Ress E., et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 114 (2000) 725-730
36. Wacheck V., Heere-Ress E., Halaschek-Wiener J., et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med 79 (2001) 587-593
37. Gleave M.E., Miayake H., and Goldie J. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 54 suppl 6A (1999) 36-46
38. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
39. Tolcher A.W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 28 suppl 15 (2001) 67-70
40. Rudin C.M., Otterson G.A., Mauer A.M., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13 (2002) 539-545
41. Marcucci G., Byrd J.C., Dai G., et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101 (2003) 425-432
42. Marshall J., Chen H., Yang D., et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 15 (2004) 1274-1283
43. Rudin C.M., Kozloff M., Hoffman P.C., et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22 (2004) 1110-1117
44. Tolcher A.W., Kuhn J., Schwartz G., et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 10 (2004) 5048-5057
45. Tolcher A.W., Chi K., Kuhn J., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
46. Marcucci G., Stock W., Dai G., et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia. Pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 23 (2005) 3404-3411
47. Gertz M.A., Geyer S.M., Badros A., et al. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma 5 (2005) 282-284
48. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141
49. Waters J.S., Webb A., Cunningham D., et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18 (2000) 1812-1823
50. Morris M.J., Tong W.P., Cordon-Cardo C., et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8 (2002) 679-683
51. O'Brien S.M., Cunningham C.C., Golenkov A.K., et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 7697-7702
52. Chanan-Khan A.A., Niesvizky R., Hohl R.J., et al. Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM). ASH Annual Meeting Abstracts 104 (2004) 1477 (abstr)
53. Kirkwood J.M., Bedikian A.Y., Millward M.J., et al. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). J Clin Oncol (Meeting Abstracts) 23 suppl 16 (2005) 7506 (abstr)
54. Rai K.R., Moore J.O., Boyd T.E., et al. Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 104 (2004) 338 (abstr)
55. Dias N., and Stein C.A. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 54 (2002) 263-269
56. Badros A.Z., Goloubeva O., Rapoport A.P., et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 23 (2005) 4089-4099
57. Bartel D.P. MicroRNAs. Fenomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
58. Lee Y., Ahn C., Han J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425 (2003) 415-419
59. Bernstein E., Caudy A.A., Hammond S.M., et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
60. Cheng A.M., Byrom M.W., Shelton J., et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33 (2005) 1290-1297
61. Calin G.A., Sevignani C., Dumitru C.D., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101 (2004) 2999-3004
62. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99 (2002) 15524-15529
63. Eis P.S., Tam W., Sun L., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102 (2005) 3627-3632
64. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102 (2005) 13944-13949
65. Mercatante D.R., Mohler J.L., and Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 277 (2002) 49374-49382
66. Ozvaran M.K., Cao X.X., Miller S.D., et al. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 3 (2004) 545-550
67. Gautschi O., Tschopp S., Olie R.A., et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 93 (2001) 463-471
68. Michels J., Johnson P.W., and Packham G. Mcl-1. Int J Biochem Cell Biol 37 (2005) 267-271
69. Le Gouill S., Podar K., and Harousseau J.L. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3 (2004) 1259-1262
70. Johnston J.B., Paul J.T., Neufeld N.J., et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 45 (2004) 2017-2027
71. Allal A.S., Waelchli L., and Brundler M.A. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 9 (2003) 6489-6496
72. Aichberger K.J., Mayerhofer M., Krauth M.T., et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML). Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105 (2005) 3303-3311
73. Sieghart W., Losert D., Strommer S., et al. Targeting Mcl1 exhibits a strong single agent activity in hepatocellular carcinoma. Eur J Cancer s2 (2004) 189 (abstr 626)
74. Thallinger C., Wolschek M.F., Maierhofer H., et al. Mcl-1 is a novel therapeutic target for human sarcoma. synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 10 (2004) 4185-4191
75. Yu C., Bruzek L.M., Meng X.W., et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24 (2005) 6861-6869
76. Walensky L.D., Kung A.L., Escher I., et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305 (2004) 1466-1470
77. Benz C.C., Keniry M.A., Ford J.M., et al. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol 37 (1990) 840-847
78. Wang J.-L., Liu D., Zhang Z.-J., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97 (2000) 7124-7129
79. Degterev A., Lugovskoy A., Cardone M., et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3 (2001) 173-182
80. Tzung S.P., Kim K.M., Basanez G., et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3 (2001) 183-191
81. Leone M., Zhai D., Sareth S., et al. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 63 (2003) 8118-8121
82. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
83. Wang J.L., Liu D., Zhang Z.J., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97 (2000) 7124-7129
84. Lickliter J.D., Wood N.J., Johnson L., et al. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 17 (2003) 2074-2080
85. Skommer J., Wlodkowic D., and Matto M. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 30 (2006) 322-331
86. Van Poznak C., Seidman A.D., and Reidenberg M.M. Oral gossypol in the treatment of patients with refractory metastatic breast cancer. A phase I/II clinical trial. Breast Cancer Res Treat 66 (2001) 239-248
87. Kitada S., Leone M., Sareth S., et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46 (2003) 4259-4264
88. Reed J.C., and Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 106 (2005) 408-418
89. Flack M., Pyle R., Mullen N., et al. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76 (1993) 1019-1024
90. Bushunow P., Reidenberg M.M., Wasenko J., et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43 (1999) 79-86
91. Becattini B., Kitada S., Leone M., et al. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol 11 (2004) 389-395
92. Liu S., Kulp S.K., Sugimoto Y., et al. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res 22 (2002) 33-38
93. Oliver C.L., Bauer J.A., Wolter K.G., et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10 (2004) 7757-7763
94. Bauer J.A., Trask D.K., Kumar B., et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells. Role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4 (2005) 1096-1104
95. Xu L., Yang D., Wang S., et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 4 (2005) 197-205
96. Olney H.J., Weng X., Watson M., et al. Preclinical evaluation of apoptosis induction by the novel small molecule BCL-2 inhibitor, GX015-070, in ex vivo chronic lymphoid leukemia (CLL) cells. J Clin Oncol (Meeting Abstracts) 23 suppl 16 (2005) 3149 (abstr)
97. McGreivy J.S., Marshall J., Cheson B.D., et al. Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor. J Clin Oncol (Meeting Abstracts) 23 suppl 16 (2005) 3180 (abstr)
98. Castro J.E., Prada C.E., Kitada S., et al. GX15-070MS, a synthetic small molecule induces apoptosis in vitro and in vivo in chronic lymphocytic leukemia. J Clin Oncol (Meeting Abstracts) 23 suppl 16 (2005) 3167 (abstr)
99. Lin B., Kolluri S.K., Lin F., et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116 (2004) 527-540